The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
Launched by NATIONAL CANCER CENTRE, SINGAPORE · Dec 7, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a drug called Bexarotene to see if it can help make chemotherapy more effective for women with metastatic triple-negative breast cancer (TNBC). TNBC is a type of breast cancer that is known to be aggressive and can be tough to treat, especially when patients have already received certain chemotherapy drugs and their cancer has continued to grow. The researchers believe that by changing the state of the cancer cells, they may be able to make them more responsive to future treatments.
To participate in this trial, women must be at least 21 years old and have been diagnosed with metastatic TNBC that has not improved after receiving prior treatment with a certain type of chemotherapy called taxanes. Participants will undergo tests to ensure they are healthy enough for the study and will have the chance to have their cancer biopsied (a small sample taken) before, during, and after the treatment. The trial is currently recruiting participants and aims to provide insight into new ways to tackle this challenging form of cancer.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients with histologically or cytologically proven metastatic TNBC
- • Patients whose TNBC has progressed after prior taxane therapy in the (neo)adjuvant or metastatic setting, and have not received Capecitabine or 5-fluorouracil
- • Females aged 21 years and older
- • ECOG performance status 0 or 1
- • Life expectancy greater than three months
- • Patients have normal organ and marrow function
- • Site(s) of disease amenable to serial bedside biopsies before, during and after study treatment
- Exclusion Criteria:
- • Previous palliative radiotherapy to potentially biopsy-able lesion
- • Active symptomatic central nervous system (CNS) metastases
- • Spinal cord compression not definitively treated with surgery and/or radiation
- • Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures
About National Cancer Centre, Singapore
The National Cancer Centre Singapore (NCCS) is a leading institution dedicated to cancer treatment, research, and education in Asia. As a premier clinical trial sponsor, NCCS focuses on advancing oncology through innovative therapies and comprehensive clinical studies. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to improving patient outcomes and contributing to global cancer research initiatives. NCCS actively collaborates with various stakeholders, including academic institutions and pharmaceutical companies, to foster groundbreaking discoveries and enhance the understanding of cancer management and treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Trial Officials
Elaine Lim, MD
Principal Investigator
National Cancer Centre, Singapore
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials